BioVex : Developing a new class of vaccines to treat and prevent cancer - OncoVEX and ImmunoVEX, and a functional genomics platform for gene determination in the nervous system - NeuroVEX
Biovex was founded in February 1999 by Dr Robert Coffin (CSO) and Professor David Latchman (Dean of the Institute of Child Heath, UK) a CEO was appointed in the same year and in mid-2000 the board was expanded with the addition of two more directors. The company was granted a core patent by the US patent office, entered the first of several collaborations and also raised £10 million in a second round financing in 2001. In June 2005 relocated its headquarters from the UK to Cambridge, Massachusetts, USA.
R&D
To view this information, you must subscribe to PL Intelligence.
Partnerships
To view this information, you must subscribe to PL Intelligence.
Deals
To view this information, you must subscribe to PL Intelligence.
Senior management
To view this information, you must subscribe to PL Intelligence.
Board of directors
To view this information, you must subscribe to PL Intelligence.
Contact details
To view this information, you must subscribe to PL Intelligence.
Head office
BioVex
34 Commerce Way
Woburn
Massachusetts
01801 Massachusetts
(USA)
All rights reserved. Terms and Conditions | Contact us
